These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 35700041)

  • 1. Morphometric imaging and quantitative susceptibility mapping as complementary tools in the diagnosis of parkinsonisms.
    Mazzucchi S; Del Prete E; Costagli M; Frosini D; Paoli D; Migaleddu G; Cecchi P; Donatelli G; Morganti R; Siciliano G; Cosottini M; Ceravolo R
    Eur J Neurol; 2022 Oct; 29(10):2944-2955. PubMed ID: 35700041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative susceptibility mapping in atypical Parkinsonisms.
    Mazzucchi S; Frosini D; Costagli M; Del Prete E; Donatelli G; Cecchi P; Migaleddu G; Bonuccelli U; Ceravolo R; Cosottini M
    Neuroimage Clin; 2019; 24():101999. PubMed ID: 31539801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative susceptibility mapping differentiates between parkinsonian disorders.
    Sjöström H; Granberg T; Westman E; Svenningsson P
    Parkinsonism Relat Disord; 2017 Nov; 44():51-57. PubMed ID: 28886909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Swallow tail sign on susceptibility map-weighted imaging (SMWI) for disease diagnosing and severity evaluating in parkinsonism.
    Liu X; Wang N; Chen C; Wu PY; Piao S; Geng D; Li Y
    Acta Radiol; 2021 Feb; 62(2):234-242. PubMed ID: 32380911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of mean diffusivity, R2* relaxation rate and morphometric biomarkers for the clinical differentiation of parkinsonism.
    Chougar L; Lejeune FX; Faouzi J; Morino B; Faucher A; Hoyek N; Grabli D; Cormier F; Vidailhet M; Corvol JC; Colliot O; Degos B; Lehéricy S
    Parkinsonism Relat Disord; 2023 Mar; 108():105287. PubMed ID: 36706616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Volume of Interest Analysis of Spatially Normalized PRESTO Imaging to Differentiate between Parkinson Disease and Atypical Parkinsonian Syndrome.
    Sakurai K; Imabayashi E; Tokumaru AM; Ito K; Shimoji K; Nakagawa M; Ozawa Y; Shimohira M; Ogawa M; Morimoto S; Aiba I; Matsukawa N; Shibamoto Y
    Magn Reson Med Sci; 2017 Jan; 16(1):16-22. PubMed ID: 27001391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining quantitative susceptibility mapping to the morphometric index in differentiating between progressive supranuclear palsy and Parkinson's disease.
    Azuma M; Hirai T; Nakaura T; Kitajima M; Yamashita S; Hashimoto M; Yamada K; Uetani H; Yamashita Y; Wang Y
    J Neurol Sci; 2019 Nov; 406():116443. PubMed ID: 31634718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism.
    Sjöström H; Surova Y; Nilsson M; Granberg T; Westman E; van Westen D; Svenningsson P; Hansson O
    Sci Rep; 2019 Apr; 9(1):6079. PubMed ID: 30988382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of apparent diffusion coefficient measurement for the differential diagnosis of multiple system atrophy, progressive supranuclear palsy, and Parkinson's disease: evaluation by 3.0-T MR imaging.
    Tsukamoto K; Matsusue E; Kanasaki Y; Kakite S; Fujii S; Kaminou T; Ogawa T
    Neuroradiology; 2012 Sep; 54(9):947-55. PubMed ID: 22274571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topographical differences of brain iron deposition between progressive supranuclear palsy and parkinsonian variant multiple system atrophy.
    Han YH; Lee JH; Kang BM; Mun CW; Baik SK; Shin YI; Park KH
    J Neurol Sci; 2013 Feb; 325(1-2):29-35. PubMed ID: 23260321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy.
    Seppi K; Schocke MF; Esterhammer R; Kremser C; Brenneis C; Mueller J; Boesch S; Jaschke W; Poewe W; Wenning GK
    Neurology; 2003 Mar; 60(6):922-7. PubMed ID: 12654954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRI evaluation of progressive supranuclear palsy: differentiation from Parkinson's disease and multiple system atrophy.
    Eraslan C; Acarer A; Guneyli S; Akyuz E; Aydin E; Colakoglu Z; Kitis O; Calli MC
    Neurol Res; 2019 Feb; 41(2):110-117. PubMed ID: 30373485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative susceptibility mapping and blood neurofilament light chain differentiate between parkinsonian disorders.
    Zhang P; Chen J; Cai T; He C; Li Y; Li X; Chen Z; Wang L; Zhang Y
    Front Aging Neurosci; 2022; 14():909552. PubMed ID: 35992605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic accuracy of Magnetic Resonance Parkinsonism Index in differentiating progressive supranuclear palsy from Parkinson's disease and controls in Indian patients.
    Sankhla CS; Patil KB; Sawant N; Gupta S
    Neurol India; 2016; 64(2):239-45. PubMed ID: 26954800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic Resonance Parkinsonism Index and midbrain to pons ratio: Which index better distinguishes Progressive Supranuclear Palsy patients with a low degree of diagnostic certainty from patients with Parkinson Disease?
    Nigro S; Morelli M; Arabia G; Nisticò R; Novellino F; Salsone M; Rocca F; Quattrone A
    Parkinsonism Relat Disord; 2017 Aug; 41():31-36. PubMed ID: 28487107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism.
    Chougar L; Arsovic E; Gaurav R; Biondetti E; Faucher A; Valabrègue R; Pyatigorskaya N; Dupont G; Lejeune FX; Cormier F; Corvol JC; Vidailhet M; Degos B; Grabli D; Lehéricy S
    Mov Disord; 2022 Jun; 37(6):1245-1255. PubMed ID: 35347754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic Resonance Imaging and Neurofilament Light in the Differentiation of Parkinsonism.
    Archer DB; Mitchell T; Burciu RG; Yang J; Nigro S; Quattrone A; Quattrone A; Jeromin A; McFarland NR; Okun MS; Vaillancourt DE
    Mov Disord; 2020 Aug; 35(8):1388-1395. PubMed ID: 32357259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simple linear brainstem MRI measurements in the differential diagnosis of progressive supranuclear palsy from the parkinsonian variant of multiple system atrophy.
    Constantinides VC; Paraskevas GP; Stamboulis E; Kapaki E
    Neurol Sci; 2018 Feb; 39(2):359-364. PubMed ID: 29196955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrain-to-pontine area ratio to differentiate progressive supranuclear palsy from Parkinson's disease and the Parkinson variant of multiple system atrophy.
    Hussl A; Mahlknecht P; Scherfler C; Esterhammer R; Schocke M; Poewe W; Seppi K
    Mov Disord; 2010 Oct; 25(14):2444-9. PubMed ID: 20878992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MR findings in the substantia nigra on phase difference enhanced imaging in neurodegenerative parkinsonism.
    Sugiyama A; Sato N; Kimura Y; Ota M; Maekawa T; Sone D; Enokizono M; Murata M; Matsuda H; Kuwabara S
    Parkinsonism Relat Disord; 2018 Mar; 48():10-16. PubMed ID: 29279191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.